This product is a human monoclonal antibody targeting HIV gp120. This antibody is identified in an HIV1-infected individual, binds to a discontinuous epitope on the HIV1 gpl20 envelopeglycoprotein, blocks the binding of gpl20 to the CD4 viral receptor, and neutralizes a broad range of HIV1 isolates.
Figure 1 Binding of α-defensins to HIV-1 gp120.
Effect of synthetic α-defensin-2on binding of different anti-gp120 mAbs with variousepitope specificities (indicated on the x-axis) in ELISA. Allthe mAbs were used at 5 ug/mL; α-defensin-2 was usedat 7.3 uM. Error bars indicate SD of mean valuesobtained from 3 repeated assays.
Furci, L., Sironi, F., Tolazzi, M., Vassena, L., & Lusso, P. (2007). α-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood, 109(7), 2928-2936.
Figure 2 Characterization of the three immunogens by Western blotting.
After SDS-PAGE and membrane transfer, protein samples of OD1, OD2, OD3 and BSA were probed with pooled serum from HIV-1 positive patients, an anti-gp120 polyclonal antibody, CD4-BS monoclonal antibodies VRC01, F105, b12, and a CD4-induced monoclonal antibody 17b.
Hu, D., Bowder, D., Wei, W., Thompson, J., Wilson, M. A., & Xiang, S. H. (2017). Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design. Vaccine, 35(23), 3067-3075.
Figure 3 Immunoprecipitation of soluble gp120 and gp140 glycoproteins.
The recognition of gp120 glycoproteins and of soluble, cleavage-defective gp140 glycoproteins by a panel of gp120-directed monoclonal antibodies was compared. Selected representative immunoprecipitations are shown. Pooled AIDS patient antisera were used to assess total envelope glycoprotein protein present in the radiolabelled 293T cell supernatants.
Wyatt, R. I. C. H. A. R. D., Desjardin, E. L. I. Z. A. B. E. T. H., Olshevsky, U., Nixon, C. H. R. I. S., Binley, J. A. M. E. S., Olshevsky, V. A. R. D. A., & Sodroski, J. O. S. E. P. H. (1997). Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. Journal of Virology, 71(12), 9722-9731.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-412 | Recombinant Anti-HIV gp120 Antibody | ELISA, WB, Dot, FuncS | IgG |
MHH-412 | Recombinant Human Anti-HIV gp120 Antibody | WB, Dot, FuncS | IgG |
HPAB-1452-FY | Human Anti-HIV gp120 Recombinant Antibody (HPAB-1452-FY) | Neut, ELISA, FC, Block | Human IgG |
HPAB-1454-FY | Human Anti-HIV gp120 Recombinant Antibody (HPAB-1454-FY) | Neut, ELISA, FC, Block | Human IgG |
FAMAB-0177WJ | Human Anti-HIV gp120 Recombinant Antibody (clone SF12) | ELISA, WB, Neut | Human IgG |
There are currently no Customer reviews or questions for FAMAB-0088WJ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.